S
chizophrenia is more often than not a chronic relapsing illness and unfortunately, it is one of the top 10 most disabling conditions in the World Health Organization's Global Burden of Disease. 1 Schizophrenia is further complicated by multiple comorbidities-both physical and psychiatric. Common physical comorbidities include cardiovascular disorders and metabolic disturbances such as lipidcholesterol abnormalities, lung disease, and heightened risk for some cancers. These added disease burdens are not chance occurrences and reflect shared genetic risks, environmental and social determinants, sedentary lifestyle, and potentially also antipsychotic drug-host interactions-all in some admixture over the course of illness.
2,3 Psychiatric and addiction comorbidities are equally common and no less problematic than the physical comorbidities. Psychiatric comorbidities include depression, anxiety, suicidality, and obsessive-compulsions. More than one-half of people with schizophrenia become depressed and 4 of 100 people with schizophrenia end their lives by suicide. 4 Substance comorbidities include abuse and misuse of cigarettes, alcohol, illicit drugs, recreational cannabis, and most often issues with polysubstance abuse. As the genetics of schizophrenia and other conditions slowly become clearer, there is evidence of overlap in genetic liability for psychosis, addictions, and more selectively, smoking. Earlier notions of drug and alcohol use as (merely) expressions of selfmedication have evolved into more complex formulations that encompass genetic risk, neurological determinants of craving and addictive behaviors, and pharmacologic modulations of anhedonia and other negative symptoms of schizophrenia. Moreover, some illicit drugs appear to be de facto causes for schizophrenia. In one recent study of the evolution of substance-induced psychosis, 47% of people went on to develop either schizophrenia or bipolar disorder. 5 And, of course, this patient group is notoriously noncompliant with medications; therefore, further undermining treatment outcomes. Collectively, these articles cover most of our present-day understanding of common comorbidities in schizophrenia. We appreciate the opportunity to bring together these experts in a single issue of the journal.
